Telesis bio stock.

Today's High Today's Low 52 Week High 52 Week Low Stock chart FL Technical Analysis Tools & Settings Open High Low Close Volume Volume remove 1DY | 5DY | 1M | 3M | …SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022.. Recent Highlights Continued execution across all areas of the growth strategy:. Increased total revenue by 98% over prior year period; …Nov 13, 2023 · Telesis Bio is a leading synthetic biology company enabling customers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the ... Oct 12, 2022 · Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ... Stock Trading Strategies All; America; Europe; Asia; Our Shows Shows Strategy Must Watch Satirical Cartoon Today's Editorial Crypto Recap Stock Picks All our investments ... Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks …

Nov 20, 2023 · The average price predicted for Telesis Bio Inc (TBIO) by analysts is $4.00, which is $3.63 above the current market price. The public float for TBIO is 8.76M, and at present, short sellers hold a 3.69% of that float. On November 20, 2023, the average trading volume of TBIO was 38.46K shares. In today’s digital age, having a short bio is essential for professionals in various fields. Whether you’re an entrepreneur, freelancer, or job seeker, a well-crafted short bio can make a lasting impression on your audience.Mar 9, 2023 · Telesis Bio. SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its ...

10 Nov 2023 ... As of November 9, 2023, Telesis Bio's shares were trading at $0.681. Over the past 52 weeks, the shares have experienced a decline of 61.71%.

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system, including BioXp 3250 system, BioXp 9600 system, and BioXp DBC, which are empowers ...Codex DNA, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 5.66 million compared to USD 2.85...A bio poem is a biography in the form of a poem that follows a strict form with 11 lines, each listing specific characteristics about a person. Bio poems are used frequently in introductory lessons about poetry writing.Telesis Bio's stock price has surged recently, but its but its P/S still remains modest. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market ...Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock Globe Newswire - Jun 5, 2023, 5:30PM

About Telesis Bio Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is …

Telesis Bio, Inc. (NASDAQ:DNAY) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.06. The firm earned $2.79 million during the quarter, compared to analyst estimates of $2.93 million.

31 May 2023 ... ... Telesis Bio through a private placement of redeemable convertible preferred stock. The private placement also includes the issuance of ...Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system, including BioXp 3250 system, BioXp 9600 system, and BioXp DBC, which are empowers ...Transcript : Telesis Bio, Inc., Q1 2023 Earnings Call, May 11, 2023 May. 11: CI Telesis Bio, Inc. Appoints Eric Esser as President May. 02: CI Telesis Bio Inc. Releases Bioxp® Select Kits to Enable DNA Amplification and Scale-Up Mar. 31: CINov 13, 2023 · Gibson Daniel Glenn, the Chief Technology Officer of Telesis Bio Inc, sale 1,190 shares at $2.83 during a trade that took place back on May 04, which means that Gibson Daniel Glenn is holding 102,083 shares at $3,363 based on the most recent closing price. Stock Fundamentals for TBIO. Current profitability levels for the company are sitting at: See the latest Telesis Bio Inc stock price (TBIO:XNAS), related news, valuation, ... Telesis Bio Inc is a synthetic biology company focused on enabling …TELESIS BIO INC's stock had its IPO on June 18, 2021, making it an older stock than just 6.05% of US equities in our set. With a year-over-year growth in debt of 193.23%, TELESIS BIO INC's debt growth rate surpasses 94.24% of about US stocks. As for revenue growth, note that TBIO's revenue has grown 81.36% over the past 12 months; that beats the …

Stock analysis for Telesis Bio Inc (DNAY:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Jun 14, 2021 · SAN DIEGO, Calif., June 14, 2021 (GLOBE NEWSWIRE) — Telesis Bio, Inc. (“Telesis Bio”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the launch of its public offering of 6.7 million shares of its common stock. The initial public offering price is ... SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its private placement of redeemable convertible preferred stock and warrants resulting in initial gross proceeds of $28.0 million to ...Shares of Telesis Bio, Inc. (TBIO Quick Quote TBIO - Free Report) have soared 77.9% since it was upgraded to a Zacks Rank #2 (Buy) on February 2. ... This stock-rating system, ...Transcript : Telesis Bio, Inc., Q1 2023 Earnings Call, May 11, 2023 May. 11: CI Telesis Bio, Inc. Appoints Eric Esser as President May. 02: CI Telesis Bio Inc. Releases Bioxp® Select Kits to Enable DNA Amplification and Scale-Up Mar. 31: CI

Telesis Bio Inc. Reports Third Quarter 2022 Financial Results. -- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021. -- BioXp® Kit Revenue increased to $884k, or 69% in ...Telesis Bio (NASDAQ:TBIO) said Wednesday it has signed an agreement with institutional investors to provide the company with funding of $28 million through a private placement of redeemable ...

About Telesis Bio Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly ® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is …Gainers telesis bio (nasdaq:tbio) shares increased by 32.5% to $0.53 during wednesday's after-market session. Femasys shares rose 19.28% and axcella health shares rose 13.1%. Gyre therapeutics stock decreased by 8.67% and impel pharmaceuticals declined by 13.3%.Oct 13, 2023 · Get Telesis Bio Inc (TBIO.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments A. Telesis Bio ( TBIO) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 13, 2023 for Q3 and the Actual Revenue was $5.6M, which ...Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023. (GlobeNewswire) Jun-05-23 05:30PM. Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock. (GlobeNewswire) -6.07%. May-31-23 05:29PM.31 May 2023 ... ... Telesis Bio through a private placement of redeemable convertible preferred stock. The private placement also includes the issuance of ...

May 11, 2023 · Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Nov 23, 2023 · This could make Telesis Bio Inc less attractive for value investors when compared to the industry median at 2.11. You can read more about Telesis Bio Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Jun 5, 2023 · SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its private placement of redeemable convertible preferred stock and warrants resulting in initial gross proceeds of $28.0 million to ... Item 1.01 Entry into a Material Definitive Agreement. On November 8, 2021, Codex DNA, Inc. (the "Company" or "Codex") entered into a Second Amendment to Loan and Security Agreement (the "LSA Amendment") with Silicon Valley Bank ("SVB"), which amended certain terms of the Company's Loan and Security Agreement with SVB dated …Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 13: CI Telesis Bio, Inc. Provides Earnings Guidance for 2023 Nov. 13: CI Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement Nov. 09Find real-time TBIO - Telesis Bio Inc stock quotes, company profile, news and forecasts from CNN Business.SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes. The press release can be accessed via the Investor section of Telesis Bio ... 4 days ago ... Title of each class. Trading Symbol(s). Name of each exchange on which registered ; Common Stock, $0.0001 par value per share. TBIO. Nasdaq ...TBIO (U.S.: Nasdaq) Overview News Telesis Bio Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.31 Market Cap $11.99 M 29.98 M Public Float...Mar 25, 2023 · Telesis Bio, Inc. (NASDAQ:TBIO) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Telesis Bio Inc., a synthetic biology company ... This could make Telesis Bio Inc less attractive for value investors when compared to the industry median at 2.11. You can read more about Telesis Bio Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.Apr 17, 2023 · Telesis Bio's stock price has surged recently, but its but its P/S still remains modest. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market ... The Last 12 Months Of Insider Transactions At Telesis Bio. Over the last year, we can see that the biggest insider purchase was by President Todd Nelson for US$192k worth of shares, at about US$1. ...

Telesis Bio, Inc. Equities TBIO US1920031010 Advanced Medical Equipment & Technology Market Closed ... Stock Telesis Bio, Inc. - Nasdaq . News Telesis Bio, Inc. Codex Dna, Inc. Announces Resignation of Jennifer Mcnealey as Chief Financial Officer, Effective from July 8, 2022. CATEGORIES. Indexes; Equities; …Nov 13, 2023 · SAN DIEGO, Nov. 13, 2023 -- Telesis Bio Inc. , a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. “This quarter, we... Nov 20, 2023 · The average price predicted for Telesis Bio Inc (TBIO) by analysts is $4.00, which is $3.63 above the current market price. The public float for TBIO is 8.76M, and at present, short sellers hold a 3.69% of that float. On November 20, 2023, the average trading volume of TBIO was 38.46K shares. Taking into account the latest results, the most recent consensus for Telesis Bio from three analysts is for revenues of US$42.2m in 2023 which, if met, would be a substantial 101% increase on its ...Instagram:https://instagram. rws holdingsback of 2009 pennymlabovinix vanguard Transcript : Telesis Bio, Inc., Q1 2023 Earnings Call, May 11, 2023 May. 11: CI Telesis Bio, Inc. Appoints Eric Esser as President May. 02: CI Telesis Bio Inc. Releases Bioxp® Select Kits to Enable DNA Amplification and Scale-Up Mar. 31: CITaking into account the latest results, the most recent consensus for Telesis Bio from three analysts is for revenues of US$42.2m in 2023 which, if met, would be a substantial 101% increase on its ... mmmw stockbmw 7401 Apr 17, 2023 · Telesis Bio and PagerDuty Surge Following Zacks Rank Upgrade Shares of Telesis Bio, Inc. ( TBIO Quick Quote TBIO - Free Report ) have soared 77.9% since it was upgraded to a Zacks Rank #2 (Buy) on ... webull margin vs cash account May 22, 2023 · SAN DIEGO, May 22, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the first commercial shipment of its BioXp ® Select DNA Cloning kit. The BioXp® Select DNA Cloning kit enables on-demand and automated assembly of DNA fragments via Gibson Assembly ... Telesis Bio. SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its ...